Envoy Medical (Envoy Medical) EPS (Basic) : $-1.20 (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Envoy Medical EPS (Basic)?

Envoy Medical's basic earnings per share (Basic EPS) for the three months ended in Mar. 2024 was $-0.32. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.20.

Envoy Medical's EPS (Diluted) for the three months ended in Mar. 2024 was $-0.32. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.20.

Envoy Medical's EPS without NRI for the three months ended in Mar. 2024 was $-0.25. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was -1.10.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Envoy Medical EPS (Basic) Historical Data

The historical data trend for Envoy Medical's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Envoy Medical EPS (Basic) Chart

Envoy Medical Annual Data

Trend

Dec21

Dec22

Dec23

EPS (Basic)

-1.05

-1.57

-2.38

Envoy Medical Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EPS (Basic)	Get a 7-Day Free Trial				-1.30	-0.70	0.07	-0.25	-0.32

Envoy Medical EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Envoy Medical's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-29.908	-	0)	/	12.553
	=	-2.38

Envoy Medical's Basic EPS for the quarter that ended in Mar. 2024 is calculated as

Basic EPS (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-6.27	-	0)	/	19.600
	=	-0.32

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.20

Envoy Medical (NAS:COCH) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Envoy Medical EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Envoy Medical's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Envoy Medical (Envoy Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Envoy Medical Inc (NAS:COCH) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

4875 White Bear Parkway, White Bear Lake, MN, USA, 55110

Website

https://www.envoymedical.com

Envoy Medical Inc is focused on designing, developing, and marketing fully implantable medical devices that improve hearing. The Company's first commercial product, the Esteem PMA application, is a fully implantable hearing device. The Esteem PMA was cleared in 2010 by the United States Food and Drug Administration. The Company intends to continue to pursue the development of a cochlear implant.